Natera, Inc.
NTRA Healthcare Diagnostics & Research
Natera, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 35.9% from fiscal 2024.
- Revenue
- +34.1%
- EPS
- +34.4%
- Free cash flow
- −85.8%
- Total debt
- −0.06%
Quarter to September 2026, against a year earlier
Follow NTRA
Alert me
Natera, Inc. (NTRA) valuation and DCF model
At $315.13 the price implies revenue of $60.40 billion by year ten, growing 35.4% a year, at a 10% free-cash-flow margin then.
- The price needs
- 35.4% a year for ten years
- $315.13
- today’s price
- Its base case
- 28.3% a year for five years, then 17.0%
- $113.28
- 64.1% below today’s price
Base case on its own ten-year record Natera, Inc.’s own growth, carried forward
Its assumptions
Powerpack lets you start from a scenario and type over any of them.
How we got there$1.31b 10 years of cash to equity+$14.79b terminal value−$80.30m net debt=$16.02b equity value÷141.39m shares=$113.28 per share
Valuation against its own history
| Multiple | Current | 5Y avg | 10Y avg | vs 10Y avg | Industry median | vs industry | 10Y range |
|---|---|---|---|---|---|---|---|
| P/FCF | 1,004.35× | 525.51× | 525.51× | 91% above | 33.51× | 2897% above | |
| P/B | 28.19× | 15.53× | 16.06× | 76% above | 3.42× | 724% above | |
| EV/Sales | 17.87× | 10.50× | 9.66× | 85% above | 5.18× | 245% above |
NTRA trades at 28.19× P/B, against a 10-year average of 16.06× (range 5.37×–28.19×). That is dearer than 100% of the last 9 year-end readings; re-rating to the average implies $179.52 per share.